Screener
PTC Therapeutics PTCT Liability Sale Of Future Royalties Noncurrent
Liability Sale Of Future Royalties Noncurrent at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept ptct:LiabilitySaleOfFutureRoyaltiesNoncurrent.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 923,604 | 968,427 |
| Operating lease liabilities- noncurrent | 90,072 | 93,583 |
| Finance lease liabilities- noncurrent | — | 3,000 |
| Liability for sale of future royalties- noncurrent | 2,022,189 | 2,025,366 |
| Other long-term liabilities | 13,704 | 13,704 |
| Total liabilities | 3,049,569 | 3,104,080 |
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025. | 81 | 80 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's liability sale of future royalties noncurrent?
- PTC Therapeutics (PTCT) reported liability sale of future royalties noncurrent of $2.02B in Q1 2026.
- How has PTC Therapeutics's liability sale of future royalties noncurrent changed year-over-year?
- PTC Therapeutics's liability sale of future royalties noncurrent increased by 9.3% year-over-year, from $1.85B to $2.02B.
- What is the long-term trend for PTC Therapeutics's liability sale of future royalties noncurrent?
- Over 5 years (2020 to 2025), PTC Therapeutics's liability sale of future royalties noncurrent has grown at a 25.2% compound annual growth rate (CAGR), from $658.74M to $2.03B.
- What does liability sale of future royalties noncurrent mean?
- This represents the long-term portion of liabilities associated with the sale of future royalty rights to third-party investors. It signifies a non-dilutive financing arrangement where the company has traded future product revenue for immediate capital. Analyzing this metric allows investors to evaluate the long-term impact of royalty monetization on the company's future top-line earnings potential.
Ask your AI about PTC Therapeutics's liability sale of future royalties noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude